Abstract:

ObjectiveTo explore the guiding role of pulmonary function assessment for drug intervention program in infants with wheezing.MethodsA total of 312 children with asthma less than or equal to 5 years old admitted to our hospital from April 2016 to March 2019 were enrolled. The children were randomly divided into observation group and control group, 156 cases in each group. During week 1-4, the children in observation group were given inhalation of glucocorticoid+beta 2 receptor agonist + oral montelukast sodium, while the children in control group were given montelukast sodium only. During week 5-8, the children in observation group were given inhalation of glucocorticoid + oral montelukast sodium, while the children in control group were given montelukast sodium only. During week 9-12, the children in observation group were given montelukast sodium only, while the control group was not given any drug intervention. The difference in asthma symptom score and the number of wheezing relapses among different groups were compared.ResultsIn the infants with positive asthma prediction index (API), moderate obstruction and positive diastolic test, the asthmatic symptoms were milder in the observation group after 8 and 12 weeks of treatment, while the asthmatic symptoms were milder in the severe obstructive patients after 4, 8 and 12 weeks of treatment(P<0.05), but there was no significant difference in the improvement of asthmatic symptoms of patients with negative API, mild obstruction and negative diastolic test between the two intervention schemes(P>0.05). The recurrence rate of wheezing within 12 weeks in positive API, moderate and severe obstruction and positive diastolic test patients was significantly lower in the observation group than in the control group(P<0.05), but there was no significant difference in the recurrence rate of negative API, mild obstruction and negative diastolic test patients between the two intervention programs(P>0.05).ConclusionFor infants with wheezing, API prediction, tidal analysis and bronchodilation test can be used to evaluate pulmonary function in the early stage of the disease, which is helpful for the scientific formulation of drug intervention programs. For children whose pulmonary function assessment suggests progress to asthma, the combination regimen of glucocorticoid, beta-2 receptor agonist and leukotriene receptor antagonist should be given as soon as possible, and the medication regimen should be adjusted according to the course and condition of the disease and family condition.

Key words:

Wheezing, Asthma, Lung function, Glucocorticoid, Leukotriene receptor antagonist, Infant